Vident Investment Advisory LLC increased its position in Johnson & Johnson (NYSE: JNJ – Get Rating) by 28.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 103,072 shares of the company stock after purchasing an additional 22,982 shares during the quarter. Vident Investment Advisory LLC’s holdings in Johnson & Johnson were worth $ 17,632,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the stock. Family CFO Inc purchased a new stake in Johnson & Johnson during the fourth quarter worth $ 26,000. Steward Financial Group LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $ 34,000. Jackson Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 1.7% during the 3rd quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company stock valued at $ 40,000 after purchasing an additional 277 shares during the last quarter. Iron Horse Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 29.9% during the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock valued at $ 45,000 after purchasing an additional 61 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Johnson & Johnson by 290.7% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock valued at $ 47,000 after purchasing an additional 218 shares during the last quarter. 68.78% of the stock is currently owned by institutional investors.
Several brokerages have recently commented on JNJ. Morgan Stanley decreased their price objective on Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Citigroup cut their target price on Johnson & Johnson from $ 210.00 to $ 205.00 in a research report on Tuesday, May 17th. Credit Suisse Group upped their target price on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Raymond James upped their target price on Johnson & Johnson from $ 195.00 to $ 196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $ 190.50.
Shares of Johnson & Johnson stock opened at $ 170.08 on Friday. The firm has a market capitalization of $ 447.55 billion, a PE ratio of 22.92, a P / E / G ratio of 3.41 and a beta of 0.66. Johnson & Johnson has a twelve month low of $ 155.72 and a twelve month high of $ 186.69. The firm’s 50-day moving average price is $ 178.35 and its 200 day moving average price is $ 172.69. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39.
Johnson & Johnson (NYSE: JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $ 2.60 by $ 0.07. The firm had revenue of $ 23.43 billion for the quarter, compared to analyst estimates of $ 23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. Johnson & Johnson’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $ 2.59 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were paid a $ 1.13 dividend. This represents a $ 4.52 dividend on an annualized basis and a yield of 2.66%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. The ex-dividend date was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is 60.92%.
In other Johnson & Johnson news, insider William Hait sold 29,699 shares of the firm’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $ 183.58, for a total value of $ 5,452,142.42. Following the transaction, the insider now directly owns 80,236 shares of the company stock, valued at approximately $ 14,729,724.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $ 173.00, for a total transaction of $ 6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $ 12,336,803. The disclosure for this sale can be found here. Insiders sold a total of 78,161 shares of company stock worth $ 13,895,302 over the last three months. Corporate insiders own 0.35% of the company stock.
Johnson & Johnson Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.